Total: $370.55M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@

Acura Pharmaceuticals Inc. (OTC BB:ACUR)

Term-loan agreement



Acura secured $600,000 through Essex Woodlands Health Ventures V LP, Care Capital Investments II LP, Care Capital Offshore Investments II LP, Galen Partners III LP, Galen Partners International III LP and Galen Employee Fund III LP (7/11)

Alchemia Ltd. (Australia; ASX:ACL)

Private placement of common stock



Alchemia raised $15.2M issuing 12.5M shares in the U.S. and 6.5M shares to existing Australian shareholders at 80 cents per share; ABN AMRO Morgans and Blueprint Life Science Group LLC served as corporate advisors (7/19)

Antares Pharma Inc. (AMEX:AIS)

Private placement of common stock and warrants

10S and W for 3.5S


Antares sold 10M common shares at $1.60 each, and warrants to purchase up to 3.5M shares at $2 per share; Oppenheimer & Co. Inc. was lead placement agent for the deal, with Punk, Ziegel & Co. and BMO Capital Markets Corp. co-placement agents (7/11)

BioAlliance Pharma SA (France; PARIS:BIO)

Private placement of common stock



BioAlliance raised $54.8M in the private placement of 3.1M shares priced at E12.79 each; the manager and bookrunner for the placement was the Paris office of Bryan, Garnier & Co. (7/26)

BrainStorm Cell Therapeutics Inc. (OTC BB:BCLI)

Private placement of common stock



Brainstorm received the first portion of an equity financing transaction from ACCBT Corp.; the total commitment is $5M (7/27)

Cell Therapeutics Inc. (CTIC)

Private placement of preferred stock and warrants



Cell Therapeutics is raising $20.25M through an offering of 3% convertible preferred stock and warrants; Rodman & Renshaw LLC served as the sole placement agent (7/26)

Curidium Medica plc (UK; LSE:CUR)

Private placement of common stock



Curidium raised $5.1M in a placement of 100M shares priced at 2.5 pence each; lead investors will receive options to buy 5M additional shares at 2.5 pence each during the next five years (7/30)

Cytogen Corp. (CYTO)

Private placement of common stock and warrants

5.8S and 2.9W


Cytogen entered purchase agreements for a private placement of 5.8M shares and 2.9M warrants to buy common shares at $1.74 each (7/2)

Dragon Pharmaceutical Inc. (Canada; TSX:DDD)

Private placement of restricted common stock



Dragon raised $1.5M offering 3.5M shares at 43 cents each (7/5)

Dynavax Technologies Corp. (DVAX)

Non-interest bearing loan



Dynavax entered a $30M financing agreement with Deerfield Management; the money can be accessed over a three-year period based on predetermined milestones (7/19)

GeoVax Labs Inc. (OTC BB:GOVX)

Private placement of common stock and warrants

22.58S and 18.3W


GeoVax is raising a total of $7.5M through PURE Capital LLC in two closings, one in August for $3.5M through the sale of 22.58M shares and 18.3M three-year warrants; the other, for $4M, will close in November and involves 25.8M shares and 16.7M warrants (7/31)

Inspire Pharmaceuticals Inc. (ISPH)

Private placement of preferred stock



Inspire agreed to sell $75M of exchangeable preferred stock based on a price of $5.35 per common share to Warburg Pincus LLC (7/18)

Neoprobe Corp. (OTC BB:NEOP)

Private placement of a convertible note and warrants



Neoprobe's CEO David Bupp and members of his family purchased a $1M note that is convertible into common stock at 31 cents per share; Neoprobe also issued 500,000 five-year warrants to purchase common stock exercisable at 31 cents per share (7/9)

Orthovita Inc. (VITA)

Registered direct offering



Orthovita raised $32.5M in an offering of 12.3M shares, priced at a 15% discount; Essex Woodlands Health Ventures was the lead investor; other investors were Lehman Brothers Inc., Magnetar Capital and affiliates of William Harris Investors Inc. (7/30)

Plethora Solutions Holdings plc (UK; LSE:PLE)

Secured loan



Plethora raised $8.1M in a loan from ETV Capital SA (7/4)**

pSivida Ltd. (Australia; PSDV)

Registered direct offering



pSivida agreed to sell about 14.4M units, priced at $1.25 apiece, each unit consisting of one ADS, which represents 10 ordinary shares, plus one warrant to purchase 0.40 ADSs at an exercise price of $1.65 per ADS (7/2)

Sangamo BioSciences Inc. (SGMO)

Private placement of common stock



Sangamo placed 3.3M shares at $9.15 each to a group of institutional investors (7/17)

VIA Pharmaceuticals Inc. (VIAP)

Private placement of common stock



VIA raised $25M selling 10.29M shares at $2.43 each; Lazard Freres & Co. LLC served as lead placement agent, with Rodman & Renshaw LLC and ThinkEquity Partners LLC (7/2)

VioQuest Pharmaceuticals Inc. (OTC BB: VQPH)

Private placement of senior convertible promissory notes and warrants



VioQuest raised $3.7M through the issuance of 8% senior convertible promissory notes, plus five-year warrants to purchase an aggregate of 2.4M shares of common stock (7/16)

WEX Pharmaceuticals Inc. (Canada; TSX:WXI)

Private placement of common stock and convertible debentures



WEX entered an agreement with CK Life Sciences International Inc., of Hong Kong, on the financing; CK Life bought about 16.3M shares at C$0.275 each, as well as C$15.6M in convertible debentures (7/16)


This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange

@ Refers to the date of the press release.

** Denotes the date the item ran in BioWorld International.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.